Read More
Madrigal Pharmaceuticals: a leader in MASH treatment with significant growth potential
Madrigal Pharmaceuticals $MDGL entered 2024 with significant success when it launched its first approved drug, Rezdiffra, for the treatment of metabolic steatohepatitis (MASH). This unique drug helps patients with moderate to advanced liver fibrosis, giving Madrigal a privileged position in a...
Read more
I read now that Trump has appointed a new Health Secretary and he is not supporting and fighting against such companies, so we'll see how this plays out now.